NVAX (56) COAG (57) REPL (46) ALVO (58) ⌘ Pro Terminal →

Maze Therapeutics Inc. (MAZE) — RQD Stock Rating Cockpit

$31.93 +0.63% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Maze Therapeutics Inc. (MAZE) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $1.77B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MAZE)Realized 20D OHLCV Swing Band: ±11.5%

RSI-14 MOMENTUMBULLISH MOMENTUM

63.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE31% OF RANGE

L: $22$31.93H: $54

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 16 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on MAZE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -6.36% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (47)

16/40 institutional & smart-money positioning score with 12/20 macro alignment.

Bull Case: Why Buyers Like MAZE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MAZE)

✓Walkthrough of MAZE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MAZE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +20.13%📐 HORIZONTAL RANGE

2026-10-30O $31.93H $32.46L $31.23C $31.93VOL 327.1K

RES: $33.61SUP: $19.16SMA50: $27.49SMA200: $31.85

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MAZE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MAZE Butterfly Map → + Track MAZE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MAZE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MAZE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MAZE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MAZE)

Health Care Rank #473 of 1016 ⚔️ NVAX vs MAZE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MAZE vs. NVAX, COAG, REPL, ALVO)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Maze Therapeutics Inc. (MAZE) ranks #473 by composite RQD confidence (45/100, grade D) and #279 by equity capitalization ($1.77B). Within this direct 5-issuer industry benchmark cohort, NVAX leads on earnings valuation at 3.9x trailing P/E, while NVAX leads on capital efficiency and profitability with 85.0% ROIC and 93.5% gross margin. ALVO currently holds the highest overall quantitative score in the immediate peer group at 58/100 (D+) compared with MAZE at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MAZE ACTIVE Maze Therapeutics Inc.	D	45/100	—	—	-35.0%	+0.63%	$1.77B	Benchmark Subject
NVAX Novavax Inc.	D+	56/100	3.9x	93.5%	85.0%	+1.45%	$1.73B	/nvax-vs-maze →
COAG Hemab Therapeutics Holdings Inc.	D+	57/100	—	—	—	+4.99%	$1.89B	/coag-vs-maze →
REPL Replimune Group Inc.	D	46/100	—	—	-35.0%	+8.28%	$1.65B	/repl-vs-maze →
ALVO Alvotech	D+	58/100	—	—	—	-1.01%	$1.91B	/alvo-vs-maze →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001842295

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Maze Therapeutics Inc. (MAZE) reported GAAP revenue of $0 (-100.0% vs. FY2024 revenue of $167.5M ) , GAAP net income of -$131.1M, operating cash flow of -$111.9M, and free cash flow of -$112.7M (-250.7% YoY). On the balance sheet, MAZE closed FY2025 with $397.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$131.1M	-$111.9M	-$112.7M	$397.1M	—
FY2024 (FY)	2024-12-31	$167.5M	$52.2M	$76.0M	$74.8M	$240.5M	—

3. MAZE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MAZE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Maze Therapeutics Inc. (NASDAQ: MAZE) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $31.93 (+0.63% 1D, market cap $1.77B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, MAZE ranks #473 in composite RQD confidence.

How does MAZE compare to NVAX and COAG in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), MAZE carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NVAX (Novavax Inc.) holds a D+ grade (56/100 RQD, P/E 3.9x, ROIC 85.0%, cap $1.73B) and COAG (Hemab Therapeutics Holdings Inc.) posts a D+ grade (57/100 RQD, P/E N/A, ROIC —, cap $1.89B). Among the 5-stock peer group, NVAX leads on earnings multiple (3.9x) while NVAX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MAZE?

Per MAZE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001842295), Maze Therapeutics Inc. generated $0 in revenue (-100.0% YoY), -$131.1M in net income, and -$112.7M in free cash flow against $397.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MAZE trading relative to its 50-day, 200-day, and 52-week technical levels?

MAZE last traded at $31.93 (+0.63% on volume of 417,943 shares), positioning the stock +16.15% above its 50-day simple moving average ($27.49) and +0.25% above its 200-day simple moving average ($31.85). Across its 52-week range of $21.95 to $53.65, MAZE sits at the 31.5% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.5% ($28.26 to $35.60).

MAZE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell MAZE stock right now?

Maze Therapeutics Inc. (MAZE) currently earns a Roarable Rating of D (Sell — SELL) with 45/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is MAZE's 12-month price target and RQD AI Jury consensus?

MAZE's 12-month base price target is $30.06 (range $23.45 to $56.33), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: MAZE RQD Cockpit MAZE 12M Forecast MAZE Earnings & Move MAZE Dividends & DRIP MAZE Insiders & 13F MAZE Whale Options MAZE Profit Sankey MAZE News & Why